Literature DB >> 18760905

Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus.

Jens P Bankstahl1, Wolfgang Löscher.   

Abstract

Status epilepticus (SE) is a neurological emergency, characterized by continuous or intermittent seizures without full recovery of consciousness between seizures, which can result in death or neurological sequelae. In about one third of patients, SE is unresponsive to sequential treatment with first- and second-line antiepileptic drugs (AEDs). At least in part, this drug resistance may be due to AED target alterations induced by SE, such as reduced membrane expression of GABA(A) receptors. Apart from target alterations by receptor trafficking, SE is known to increase the brain expression of drug efflux transporters such as P-glycoprotein (Pgp), which might reduce concentrations of AEDs at their brain targets. However, it is not known whether overexpression of Pgp develops rapidly enough after onset of SE to be of any functional consequence for drug treatment. Therefore, we studied whether overexpression of Pgp at the blood-brain barrier is involved in refractory SE. Two rat SE models were used, the lithium/pilocarpine model and induction of SE by sustained electrical stimulation of the basolateral amygdala (BLA). Four AEDs, diazepam (DZP), phenobarbital (PB) and phenytoin (PHT) or fosphenytoin (FPHT) were administered at different times after onset of SE. In the pilocarpine model, once self-sustained SE was established, none of the AEDs alone was effective in terminating SE, but sequential injection of PB and DZP stopped SE. Administration of the Pgp inhibitor tariquidar did not prevent or counteract resistance to AEDs. In the BLA model, DZP and PB terminated SE in the majority of rats, whereas PHT or FPHT were ineffective. Immunohistochemical staining of Pgp did not indicate any increase of Pgp expression in brain capillary endothelial cells during SE, whereas significant overexpression was determined in both models 48 h after SE. The data suggest that, at least under the conditions of the present study, alterations in Pgp are not critically involved in refractory SE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18760905     DOI: 10.1016/j.eplepsyres.2008.07.007

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  20 in total

1.  The onset of acute oxcarbazepine toxicity related to prescription of clarithromycin in a child with refractory epilepsy.

Authors:  Raoul Santucci; Helen Fothergill; Vincent Laugel; Anne Perville; Anne De Saint Martin; Anne-Cécile Gerout; Michel Fischbach
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

Review 2.  Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research.

Authors:  Wolfgang Löscher; Claudia Brandt
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 3.  Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy.

Authors:  Wolfgang Löscher; Oliver Langer
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

4.  P-gp Protein Expression and Transport Activity in Rodent Seizure Models and Human Epilepsy.

Authors:  Anika M S Hartz; Anton Pekcec; Emma L B Soldner; Yu Zhong; Juli Schlichtiger; Bjoern Bauer
Journal:  Mol Pharm       Date:  2017-03-02       Impact factor: 4.939

5.  Status epilepticus.

Authors:  Panayiotis N Varelas; Marek A Mirski
Journal:  Curr Neurol Neurosci Rep       Date:  2009-11       Impact factor: 5.081

6.  Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.

Authors:  Florian Bauer; Claudia Kuntner; Jens P Bankstahl; Thomas Wanek; Marion Bankstahl; Johann Stanek; Severin Mairinger; Bernd Dörner; Wolfgang Löscher; Markus Müller; Thomas Erker; Oliver Langer
Journal:  Bioorg Med Chem       Date:  2010-06-22       Impact factor: 3.641

Review 7.  Status epilepticus: an update.

Authors:  Panayiotis N Varelas; Marianna V Spanaki; Marek A Mirski
Journal:  Curr Neurol Neurosci Rep       Date:  2013-07       Impact factor: 5.081

8.  Alteration in P-glycoprotein functionality affects intrabrain distribution of quinidine more than brain entry-a study in rats subjected to status epilepticus by kainate.

Authors:  Stina Syvänen; Maarten Schenke; Dirk-Jan van den Berg; Rob A Voskuyl; Elizabeth C de Lange
Journal:  AAPS J       Date:  2012-01-04       Impact factor: 4.009

9.  The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: a positron emission tomography study.

Authors:  Severin Mairinger; Jens P Bankstahl; Claudia Kuntner; Kerstin Römermann; Marion Bankstahl; Thomas Wanek; Johann Stanek; Wolfgang Löscher; Markus Müller; Thomas Erker; Oliver Langer
Journal:  Epilepsy Res       Date:  2012-02-17       Impact factor: 3.045

10.  Combined effects of epileptic seizure and phenobarbital induced overexpression of P-glycoprotein in brain of chemically kindled rats.

Authors:  Xinyue Jing; Xiang Liu; Tao Wen; Shanshan Xie; Dan Yao; Xiaodong Liu; Guangji Wang; Lin Xie
Journal:  Br J Pharmacol       Date:  2010-03-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.